Saruplase
Highest phase reached
Phase 2
Drug type
Enzyme
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Enzyme
- Drug name
- Saruplase
- cg 4509
- CG 4509
- CG-4509
- cg4509
- Cg4509
- KINASE (ENZYME-ACTIVATING), PROURO- (HUMAN CLONE PUK33 REDUCED)
- KINASE (ENZYME-ACTIVATING), PROURO- (HUMAN CLONE PUK4/PUK18 PROTEIN MOIETY REDUCED)
- kinase enzyme activating prouro human clone puk33 reduced
- kinase enzyme activating prouro human clone puk4 puk18 protein moiety reduced
- plasminogen activator pro human liver urokinase type protein moiety reduced
- PLASMINOGEN ACTIVATOR, PRO- (HUMAN LIVER UROKINASE-TYPE PROTEIN MOIETY REDUCED)
- PROUROKINASE (ENZYME ACTIVATING) (HUMAN CLONE PUK4/PUK18), NONGLYCOSYLATED
- prourokinase enzyme activating human clone puk4 puk18 nonglycosylated
- saruplasa
- Saruplasa
- saruplase
- Saruplase
- saruplase [INN]
- SARUPLASE [MI]
- Saruplase [WHO-DD]
- saruplase inn
- saruplase mi
- saruplase who dd
- scupa
- Scupa
And 2 more, listed on the interactive page.
- ATC classification codes
- B01AD08
Sources for recorded values
- CAS registry numbers
- 99149-95-8
- ChEMBL ID
- CHEMBL2108129
- FDA ingredient codes (UNII)
- U5NH2JV64T
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -ase
Investigated indications
- Condition
- Thrombosis
- Highest recorded phase
- 4
- Condition identifier
- HP:0004419
- Subject identifier
- D013927
- Condition identifier
- HP_0004419
- Condition identifier
- HP_0004419
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0000831
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (19)
- A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer
- A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.
- A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
- A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
- ALDH Enzyme in CRF With Advanced GI Cancer
- An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
- Clinical Evaluation of Arthrocentesis, Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor in Treatment of Temporo-Mandibular Joint Anterior Displacement
- Effect of Digestive Enzymes as Add on Therapy on Patients With Functional Dyspepsia.
- Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance
- Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease
- In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme
- Intestinal Microbiota Composition in Patients With Chronic Pancreatitis and Pancreatic Exocrine Insufficiency
- Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
- Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
- Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
- Search for Serum/Plasma Biomarkers in Pompe's Disease
- The Effect of Enzyme Replacement Therapy in Mucopolysaccharidosis
- Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas